Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
On Channel 4 (https://www.channel4.com/programmes/can-we-cure-kids-cancer/on-demand/70101-001), really really tough watch at times (understatement). Please be prepared for a deeply saddening watch.
This is real hint at the sort of technology Avacta may be on the cusp of revolutionising on a grand scale. Immunotherapies shown. Also shows Doxorubicin in action and its harrowing side effects, how effective this chemo can be but how dangerous the side effects are too.
I would whip my (somewhat) considerable investment out for a value of nothing in an instant if it meant Avacta were to be successful, to any degree, with what they are hoping to achieve.
Was just going off the Actual Study Start Date rather than date of first dosage.
Actual Study Start Date : July 16, 2021
"The actual date on which the first participant was enrolled in a clinical study."
https://clinicaltrials.gov/ct2/show/NCT04969835
Mr Andy Hayes (Sarcoma surgeon) re. Sarcoma - "There are more than 50 types, which can make it extremely difficult to find treatments that are effective."
The AVA6000 trial criteria states: "The tumour types to be explored in Phase 1b, will be determined based on evaluation of the Phase 1a data and the protocol will be amended accordingly."
AS has already iterated Sarcoma & Ovarian will be the two tumour types in P2.
Avacta chose a type of cancer to carry out their pre-clinical trials on with. This was a xenografted human sarcoma. We are now over a year(!) into the trial and the same cancer type has been specifically chosen, on assessment of full data, to progress with. I don't believe this to be coincidental.
This cancer type is extremely difficult to effectively treat, and Avacta are currently treating it (and other cancers) at a dose equiv. of 108mg of Dox - the recommended dose is 60-70mg and even at this level the side-effects are harrowing, let alone at one >150% of this.
For those that struggle to decipher the impact of this - not being able to find a MTD (maximum tolerated dose) as Avacta are not only saying, but currently showing, in the DE phase is gargantuan in what it shows. Traditional Dox has an MTD because of the severity of the side-effects seen.
Have a good day all.
5,500 sq ft upgraded to 8,800 sq ft (8 modules of 1,100 ea.)
https://www.scalespace.co.uk/news/scale-space-launches-16900-sq-ft-of-lab-space-in-white-city-innovation-district-and-signs-five-new-life-sciences-tenants
We're all down the Wetherby Whaler for an all day pish up. Plenty of fun and games, pin the Affimer on the test strip starting shortly. How many shumpers can one person wear was a blast. Big Al just done a shoey, it's getting lively.. :- )
I will keep this swift. Soft reminder to all, RH's & MK's family investments total well in excess of 12m shares of Avacta AFAIK. That's me only touching on openly reported ownerships. All within AIM regulations before any hawks swoop in. Aside from that - they have already totalled a multi-6 figure sum expenditure on Med19 itself. Not to touch on Saturn Pass et all.
They aren't here to sell to you and I to claw back what they have laid out only. Widen the horizon of thought and you will see their aim and perhaps, just maybe, you will see it unfold, too.
Rome wasn't built in a day and nor was this solid based BioTech. Have a good week, or two... all.
139 days since first in-human dosing of AVA6000. Almost 5 months. The data-set (they are aiming for as heavily data filled trials for full clarity) is building. FDA has granted IND application based on assessing the majority of this data.
AVA6000 is the first piece of weaponry in a large warchest.
Avacta have created the most efficcient LFT on the market. It is also, funnily enough, data-rich with performance amongst a varied CT value spectrum. It has shown its hand that other companies can't beat on performance. It does not rely on traditional monoclonal antibodies like other tests, of which are in supreme demand.
Just because we currently have no visibility of marketing, sales, manufacturing it does not mean it is not happening.
Contracts will, in my opinion, have been signed for the sale of MeduFlow. They sell every little test they make.
Happy new year Abaktarians.
Having two shorts in place is perversely great news when one needs the liquidity and/or cuts their losses and bails. Like a coiled spring with the added bonus of traders & holders alike jumping on the back of it too further the momentum of the rise.
May be small positions for them both respectively but I sense it may be a costly one for at least one of the two companies. Part of me hopes they stay in their positions throughout the AVA journey(s). How embarrassing & essentially immoral would that be viewed on top of monumental cash losses if/when the entire chemotherapy world has been revolutionised in so many respects.
Have a good Friday all, I think we will....
Wrong thread. But FWIW taken from the Avacta Learning application notes (http://learning.avactalifesciences.com/delta-app-note)
"Conclusion
Based on the results of the analysis above, this study showed conclusively that the Avacta AffiDX® SARS-CoV-2 Antigen Lateral Flow Test device is confirmed as being able to detect the SARS-CoV-2 Delta Variant of Concern in routine samples.
The SARS-CoV-2 Delta variant has a higher transmission rate and is prevalent in many countries. Rapid lateral flow COVID-19 tests are commonly used across the world for mass screening; hence it is important that these rapid antigen tests are accurately evaluated against the Delta variant. Very few SARS-CoV-2 rapid antigen tests that are currently available in the market have been clinically evaluated against the Delta variant and these studies are usually conducted based on in-silico laboratory approach instead of using real-life patient samples. In this study, the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test was independently validated against Delta Variant of Concern using routine, prospective clinical samples. The AffiDX® SARS-CoV-2 Antigen Lateral Flow Test uses novel Affimer® technology which is highly sensitive and specific for the detection of SARS-CoV-2 antigens in human anterior nasal swab samples.
This study provides further evidence that Affimer® technology can be successfully applied to rapid antigen diagnostic platforms. "
https://www.mpo-mag.com/contents/view_breaking-news/2021-10-11/deal-transforms-mologic-into-social-enterprise/
For those wanting a read
You can see these travelling back into Reykjavik (Iceland) - very fascinating pieces of kits & totally utilitarian in that they are heated solely hydroelectrically & geothermally. They grow all sorts, supply a lot of the country's fruit & veg (including bananas) and taste great.
Wonderful place, well worth a visit. I may even sell a couple dozen AVCT shares to fund another trip there in a couple of years time.
The demand certainly is exploding. The message is being hit home in many countries.
https://www.irishtimes.com/news/health/sales-of-covid-antigen-tests-expected-to-rise-in-run-up-to-christmas-1.4726211
https://www.irishtimes.com/news/health/antigen-tests-should-be-used-twice-weekly-by-people-doing-high-risk-activities-nphet-1.4726688
https://www.irishtimes.com/news/politics/antigen-tests-to-be-sold-at-subsidised-prices-amid-concerning-rise-in-covid-cases-1.4727431
Brilliant post Lilarch. The sheer depth of experience they have in just the therapeutic division alone is mind-blowing.
Also it's no coincidence Affimers are the magic bean to the highest efficacy LFT there is on the market for COVID. It will do the same for other LFT's targeting other usages.
Good weekend all. I certainly am going to as I have a rather good feeling about November :- )